Cardiopulmonary FunctionNCT07005193
Effects of LPG and Ventilation Interventions on Reducing HAP and Improving Cardiopulmonary Health
A study testing Cooking ventilation facilities, Using liquefied gas for cooking and Using solid fuels for cooking in people with Cardiopulmonary Function and Environmental Exposures, run by Huazhong University of Science and Technology at 3 sites in China.
Trial summary
The goal of this clinical trial is to evaluate the independent and synergistic effects of liquefied petroleum gas (LPG) substitution and improved ventilation on household air pollution (HAP) reduction and cardiopulmonary health. The main questions it aims to answer are: 1. Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Cardiopulmonary Function, Environmental Exposures
- What is being tested?
- Cooking ventilation facilities, Using liquefied gas for cooking and Using solid fuels for cooking
- Type of treatment
- Medical device, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,200 participants
- Where
- 3 sitesChina
- Study dates
- 1 Jul 2025to 30 Jun 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
- Inclusion Criteria Primary Participants：
- Aged 18-75 years;
- Local permanent residents with no plans for long-term travel or relocation within one year;
- Kitchen suitable for installation of ventilation facilities;
- Responsible for daily household cooking, cooking ≥5 times per week;
- To control for community penetration of pollution, households will be preferentially recruited in naturally ventilated, open villages, avoiding valleys or basins that hinder pollutant dispersion; preference for detached houses with ≥10 m distance from neighboring kitchens and well-sealed doors and windows. Secondary Participants:
- Elderly individuals aged 65-75 living with the primary participant;
- Children aged 3-6 living in the same household.
- Exclusion Criteria:
- Clinical diagnosis of major chronic diseases such as severe respiratory diseases, cardiovascular diseases, malignant tumors, or end-stage renal disease;
- Pregnant or breastfeeding women;
- Current smokers or individuals with self-reported exposure to productive dust or other occupational hazards;
- Individuals who are unable to fully understand the study process or clearly express their own complaints, such as those with psychiatric disorders or severe neuroses, or who cannot cooperate with the study for other reasons.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
China3 sites, 3 recruiting
- Recruiting
Hong'an County Health Center
Huanggang, Hubei, 438000
Kuai Yu, Doctor, +86 15172473088
Hao Wang, Doctor, +8618623910286, wanghaogongwei@163.com
- Not yet recruiting
Longhui County Health Center
Shaoyang, Hunan, 422000
Kuai Yu, Doctor, +86 15172473088, yukuai5200@163.com
Hao Wang, Doctor, +8618623910286, wanghaogongwei@163.com
- Not yet recruiting
Suiping County Health Center
Zhumadian, Henan, 4630000
Kuai Yu, Doctor, +86 15172473088, yukuai5200@163.com
Hao Wang, Doctor, +8618623910286, wanghaogongwei@163.com
About this study
Official title: Effects of Liquefied Petroleum Gas and Ventilation Interventions on Reducing Household Air Pollution From Solid Fuel Use and Improving Cardiopulmonary Health: A Multi-center, 2×2 Factorial Randomized Controlled Trial
The goal of this clinical trial is to evaluate the independent and synergistic effects of liquefied petroleum gas (LPG) substitution and improved ventilation on household air pollution (HAP) reduction and cardiopulmonary health. The main questions it aims to answer are:
- Does LPG substitution or improved ventilation reduce HAP and improve cardiopulmonary health?
- Would the combined intervention of LPG substitution and improved ventilation outperform single interventions?
- What is the cost-effectiveness of such interventions, and are they sustainable?
- Does the intervention reduce the incidence of cardiopulmonary clinical events?
Read more
Participants will be randomized in 4 groups:
A: Solid fuel + no ventilation facilities group (300 households): Continued use of solid fuels without installation of ventilation facilities and receipt of standardized health education. No LPG stoves or ventilation equipment will be provided during the intervention period. However, after the primary endpoint assessment at 12 months, all households in Group A will be provided with LPG stoves and ventilation facilities of equivalent specifications free of charge, along with health guidance. Phased cash compensation will be provided during the intervention period.
B: Liquefied petroleum gas (LPG) + no ventilation facilities group (300 households): Provided with LPG stoves and instructed to use them during cooking, with regular LPG supply throughout the intervention period. Participants will also receive standardized health education.
C: Solid fuel + ventilation facilities group (300 households): Continued use of solid fuels while being provided with ventilation facilities and instructed to use them during cooking. Electricity costs will be compensated during the intervention period. Participants will also receive standardized health education.
D: LPG + ventilation facilities group (300 households): Provided with both LPG stoves and ventilation facilities and instructed to use both during cooking. Regular LPG supply and electricity cost compensation will be provided throughout the intervention period. Participants will also receive standardized health education.
- Conditions
- Cardiopulmonary Function, Environmental Exposures
- Being tested
- Cooking ventilation facilities, Using liquefied gas for cooking, Using solid fuels for cooking, No ventilation during cooking
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cooking ventilation facilitiesDevice
Installation and use of kitchen ventilation facilities (e.g., range hood) during cooking to reduce indoor air pollution exposure.
Using liquefied gas for cookingBehavioural
Households are provided with liquefied gas stoves and encouraged to use liquefied gas instead of solid fuels for cooking.
Using solid fuels for cookingBehavioural
Households continue using traditional solid fuels (e.g., coal or biomass) for cooking according to their usual practices.
No ventilation during cookingBehavioural
Households continue cooking without installing additional ventilation facilities during the intervention period.
| Study group | Role | What they receive |
|---|---|---|
| A: Solid fuel + no ventilation (control). | Other | Solid fuel + no ventilation facilities group: Continued use of solid fuels without installation of ventilation facilities and receipt of standardized health education. No LPG stoves or ventilation equipment will be provided during the intervention period. However, after the primary endpoint assessment at 12 months, all households in Group A will be provided with LPG stoves and ventilation facilities of equivalent specifications free of charge, along with health guidance. Phased cash compensation will be provided during the intervention period. Receives: Behavioral: Using solid fuels for cooking; Behavioral: No ventilation during cooking |
| B: LPG + no ventilation. | Experimental | Liquefied petroleum gas (LPG) + no ventilation facilities group: Provided with LPG stoves and instructed to use them during cooking, with regular LPG supply throughout the intervention period. Participants will also receive standardized health education. Receives: Behavioral: Using liquefied gas for cooking; Behavioral: No ventilation during cooking |
| C: Solid fuel + ventilation. | Experimental | Solid fuel + ventilation facilities group: Continued use of solid fuels while being provided with ventilation facilities and instructed to use them during cooking. Electricity costs will be compensated during the intervention period. Participants will also receive standardized health education. Receives: Device: Cooking ventilation facilities; Behavioral: Using solid fuels for cooking |
| D: LPG + ventilation. | Experimental | LPG + ventilation facilities group: Provided with both LPG stoves and ventilation facilities and instructed to use both during cooking. Regular LPG supply and electricity cost compensation will be provided throughout the intervention period. Participants will also receive standardized health education. Receives: Device: Cooking ventilation facilities; Behavioral: Using liquefied gas for cooking |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in the Number of Ultrafine particles (UFP)
Unit: particles/cm³, Measuring instrument: TSI NanoScan (TSI, USA), MicroPEM (PennEngineering, USA), Gillian5000 (Sensidyne, USA), Measurement method: Monitoring device sensors.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Concentrations of PM2.5
Unit: ug/m3, Measuring instrument: TSI NanoScan (TSI, USA), MicroPEM (PennEngineering, USA), Gillian5000 (Sensidyne, USA), Bbair (Yuanrui Environmental Protection Technology Co., Ltd, China) , Measurement method: Monitoring device sensors.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Heart Rate Variability (HRV) Measured by 12-lead ECG
Heart rate variability measured using standard 12-lead electrocardiogram (ECG). Measuring instrument: HeaLink heart rate sensor (Henan Link Medical Technology Co., Ltd., China), The time-domain indicators include:SDNN: Standard deviation of all normal-to-normal (NN) intervals over 24 hours / SDANN: Standard deviation of the average NN intervals calculated over 5-minute segments throughout 24 hours / RMSSD: Root mean square of successive differences between adjacent NN intervals over 24 hours.
The frequency-domain indicators include: TP: Total power / LF: Low-frequency power / HF: High-frequency power / LF/HF: Ratio of low-frequency to high-frequency power.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Forced Vital Capacity (FVC)
Forced Vital Capacity measured using spirometer (HI105; Chestgraph, Japan). Units of Measure: Liters. Method of Measurement: Standardized spirometric testing protocol.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Forced Expiratory Volume in 1 Second (FEV1)
Forced Expiratory Volume in 1 Second measured using spirometer (HI105; Chestgraph, Japan). Units of Measure: Liters. Method of Measurement: Standardized spirometric testing protocol.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Secondary outcomes (29)
Change in the Concentrations of Specific Chemical Components in Particulate Matter
Unit: ug/m3, Measuring instrument: Gilian (Sensidyne, USA), PEM-2-2.5 (MSP,USA), Measurement method: ICP-MS (Inductively Coupled Plasma Mass Spectrometry) and GC-MS/MS (Gas Chromatography-Tandem Mass Spectrometry).
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Concentrations of Ozone (O₃)
Unit: ug/m3, Measuring instrument: AEROQUAL Series 500 (Aeroqual, New Zealand), Measurement method: Monitoring device sensors.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Concentrations of Black Carbon (BC)
Unit: ug/m3, Measuring instrument: Model AE51 (AethLabs, USA), Measurement method: Monitoring device sensors.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Systolic and Diastolic Blood Pressure
Unit: mmHg, Instrument: Omron (Japan);
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Fractional Exhaled Nitric Oxide (FeNO)
Unit: ppb , Instrument: NIOX VERO (Aerocrine AB; Solna, Sweden);
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Pulse Wave Velocity (PWV)
Assessed using an arterial stiffness analyzer (Itamar Medical, Israel) to measure arterial stiffness in meters per second (m/s).
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Incidence of Obesity and Central Obesity
Obesity defined as body mass index (BMI) ≥28.0 kg/m²; central obesity defined as waist circumference ≥90 cm for men or ≥85 cm for women.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Incidence of Diabetes
Diagnostic criteria based on the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020). Defined as any of the following: fasting plasma glucose ≥7.0 mmol/L (confirmed by repeat testing), 2-h plasma glucose ≥11.1 mmol/L after a 75 g oral glucose tolerance test, HbA1c ≥6.5%, or random plasma glucose ≥11.1 mmol/L with typical hyperglycemic symptoms, or physician-diagnosed diabetes with initiation of glucose-lowering therapy during follow-up.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Incidence of Dyslipidemia
Diagnostic criteria based on the Chinese Guidelines for the Management of Dyslipidemia in Adults (2016). Defined as any of the following without lipid-lowering therapy: total cholesterol (TC) ≥6.2 mmol/L, triglycerides (TG) ≥2.3 mmol/L, low-density lipoprotein cholesterol (LDL-C) ≥4.1 mmol/L, or high-density lipoprotein cholesterol (HDL-C) <1.0 mmol/L, or physician-diagnosed dyslipidemia with initiation of lipid-lowering treatment during follow-up.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Incidence of Hypertension
Diagnostic criteria based on the Chinese Guidelines for the Prevention and Treatment of Hypertension (2024). Defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg measured on three separate occasions without antihypertensive treatment, or physician-diagnosed hypertension with initiation of antihypertensive therapy during follow-up.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Incidence of Acute Exacerbation of Chronic Bronchitis
Measurement method: modified Anthonisen criteria. Participants with baseline chronic cough and sputum (≥3 months per year for ≥2 consecutive years) who develop acute worsening of ≥1 core symptom lasting ≥2 days (increased dyspnea, increased sputum volume, or purulent sputum) leading to activity limitation or additional medical treatment (e.g., antibiotics, oral corticosteroids, or clinical visit).
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Incidence of Acute Respiratory Infection
Measurement method: weekly electronic diary (eDiary/ePRO) recording new respiratory symptoms in the past 7 days, including onset time, body temperature, and symptom spectrum. Acute respiratory infection is defined as ≥2 respiratory symptoms. For eligible cases, an "infection event form" will be initiated to record healthcare utilization, testing, and medication. A new episode is defined as recurrence after ≥7 symptom-free days.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Forced Expiratory Flow at 75% of FVC (FEF75)
Forced Expiratory Flow at 75% of Forced Vital Capacity measured in Liters/Second. Units of Measure: Liters/Second. Method of Measurement: Standardized spirometric testing protocol.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Forced Expiratory Flow at 50% of FVC (FEF50)
Forced Expiratory Flow at 50% of Forced Vital Capacity measured in Liters/Second. Units of Measure: Liters/Second. Method of Measurement: Standardized spirometric testing protocol.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Forced Expiratory Flow at 25% of FVC (FEF25)
Forced Expiratory Flow at 25% of Forced Vital Capacity measured in Liters/Second. Method of Measurement: Standardized spirometric testing
Measured: 1 year, with follow-ups at 6, 1 protocol.2, 24, and 36 months
Change in the Peak Expiratory Flow (PEF)
Peak Expiratory Flow measured using spirometer (HI105; Chestgraph, Japan).Units of Measure: Liters/Second. Method of Measurement: Standardized spirometric testing protocol.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Cardio-Ankle Vascular Index (CAVI)
Measured using arterial stiffness analyzer (Itamar Medical, Israel) to assess arterial stiffness.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Peripheral Arterial Tone (PAT) Index
Assessed using the EndoPAT noninvasive endothelial function detection system (Itamar Medical, Israel).
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Environmental Noise Level
Unit: dB, Measuring instrument: Model ASV5910+ (Aihua Instruments Co., Ltd, China) , Measurement method: Monitoring device sensors.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Concentrations of Internal Exposure to PAHs and VOCs
Unit: ng/mL, Measuring samples: Urine samples, Measurement method: GC-MS/MS.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Concentrations of Internal Exposure to Metal Elements
Unit: ng/mL, Measuring samples: Blood and urine samples, Measurement method: ICP-MS.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Concentrations of Total Volatile Organic Compounds (TVOCs)
Unit: ug/m3, Measuring instrument: Model TG-503 (GrayWolf, USA), Measurement method: Monitoring device sensors
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Concentrations of Nitrogen Dioxide (NO₂)
Unit: ug/m3, Measuring instrument: AEROQUAL Series 500 (Aeroqual, New Zealand) , Measurement method: Monitoring device sensors.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Concentrations of PM1 / PM10
Unit: ug/m3, Measuring instrument: TSI NanoScan (TSI, USA), MicroPEM (PennEngineering, USA), Gillian5000 (Sensidyne, USA), Bbair (Yuanrui Environmental Protection Technology Co., Ltd, China) , Measurement method: Monitoring device sensors.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in Air Temperature
Unit: °C, Measuring instrument: HOBO temperature loggers, Measurement method: monitoring device sensors.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in Relative Humidity
Unit: %, Measuring instrument: HOBO humidity loggers, Measurement method: monitoring device sensors.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in Wind Speed
Unit: m/s, Measuring instrument: Portable ultrasonic anemometer (FT702LT/D-V22-FF, UK), Measurement method: monitoring device sensors.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in Wind Direction
Unit: degrees (°), Measuring instrument: Portable ultrasonic anemometer (FT702LT/D-V22-FF, UK), Measurement method: monitoring device sensors.
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Environmental Microbial Aerosols
Unit: copies/m³ or CFU/m³, Measuring instrument: Liquid-based bioaerosol samplers (BioSampler, SpinCon), Measurement method: Molecular biological detection (e.g., nucleic acid extraction and PCR-based analysis).
Measured: 1 year, with follow-ups at 6, 12, 24, and 36 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jun 2025
- Study start1 Jul 2025
- Primary completion30 Jun 2029 (estimated)
- Study completion30 Jun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiopulmonary FunctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Enrolment
- 1,200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Huazhong University of Science and Technology
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kuai Yu, Huazhong University of Science and Technology
- Investigators
- Kuai Yu, Principal investigator, Huazhong University of Science and Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07005193
- Sponsor's protocol ID
- 2023ZD0509900
- Status last verified
- Feb 2026
- First submitted
- 8 May 2025
- Last updated
- 17 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Liquefied Petroleum Gas and Ventilation Interventions on Reducing Household Air Pollution From Solid Fuel Use and Improving Cardiopulmonary Health: A Multi-center, 2×2 Factorial Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07005193
- Acronym / sponsor ID
- 2023ZD0509900
- Conditions
- Cardiopulmonary Function, Environmental Exposures
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 1,200 participants (estimated)
- Lead sponsor
- Huazhong University of Science and TechnologyUniversity, hospital or other
- Study start
- 1 Jul 2025 (actual)
- Primary completion
- 30 Jun 2029 (estimated)
- Study completion
- 30 Jun 2029 (estimated)
- First posted
- 5 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate the independent and synergistic effects of liquefied petroleum gas (LPG) substitution and improved ventilation on household air pollution (HAP) reduction and cardiopulmonary health. The main questions it aims to answer are:
- Does LPG substitution or improved ventilation reduce HAP and improve cardiopulmonary health?
- Would the combined intervention of LPG substitution and improved ventilation outperform single interventions?
- What is the cost-effectiveness of such interventions, and are they sustainable?
- Does the intervention reduce the incidence of cardiopulmonary clinical events?
Participants will be randomized in 4 groups:
A: Solid fuel + no ventilation facilities group (300 households): Continued use of solid fuels without installation of ventilation facilities and receipt of standardized health education. No LPG stoves or ventilation equipment will be provided during the intervention period. However, after the primary endpoint assessment at 12 months, all households in Group A will be provided with LPG stoves and ventilation facilities of equivalent specifications free of charge, along with health guidance. Phased cash compensation will be provided during the intervention period.
B: Liquefied petroleum gas (LPG) + no ventilation facilities group (300 households): Provided with LPG stoves and instructed to use them during cooking, with regular LPG supply throughout the intervention period. Participants will also receive standardized health education.
C: Solid fuel + ventilation facilities group (300 households): Continued use of solid fuels while being provided with ventilation facilities and instructed to use them during cooking. Electricity costs will be compensated during the intervention period. Participants will also receive standardized health education.
D: LPG + ventilation facilities group (300 households): Provided with both LPG stoves and ventilation facilities and instructed to use both during cooking. Regular LPG supply and electricity cost compensation will be provided throughout the intervention period. Participants will also receive standardized health education.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| A: Solid fuel + no ventilation (control). | Other | Behavioral: Using solid fuels for cooking, Behavioral: No ventilation during cookingSolid fuel + no ventilation facilities group: Continued use of solid fuels without installation of ventilation facilities and receipt of standardized health education. No LPG stoves or ventilation equipment will be provided during the intervention period. However, after the primary endpoint assessment at 12 months, all households in Group A will be provided with LPG stoves and ventilation facilities of equivalent specifications free of charge, along with health guidance. Phased cash compensation will be provided during the intervention period. |
| B: LPG + no ventilation. | Experimental | Behavioral: Using liquefied gas for cooking, Behavioral: No ventilation during cookingLiquefied petroleum gas (LPG) + no ventilation facilities group: Provided with LPG stoves and instructed to use them during cooking, with regular LPG supply throughout the intervention period. Participants will also receive standardized health education. |
| C: Solid fuel + ventilation. | Experimental | Device: Cooking ventilation facilities, Behavioral: Using solid fuels for cookingSolid fuel + ventilation facilities group: Continued use of solid fuels while being provided with ventilation facilities and instructed to use them during cooking. Electricity costs will be compensated during the intervention period. Participants will also receive standardized health education. |
| D: LPG + ventilation. | Experimental | Device: Cooking ventilation facilities, Behavioral: Using liquefied gas for cookingLPG + ventilation facilities group: Provided with both LPG stoves and ventilation facilities and instructed to use both during cooking. Regular LPG supply and electricity cost compensation will be provided throughout the intervention period. Participants will also receive standardized health education. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cooking ventilation facilitiesInstallation and use of kitchen ventilation facilities (e.g., range hood) during cooking to reduce indoor air pollution exposure. | Device | C: Solid fuel + ventilation., D: LPG + ventilation. |
| Using liquefied gas for cookingHouseholds are provided with liquefied gas stoves and encouraged to use liquefied gas instead of solid fuels for cooking. | Behavioural | B: LPG + no ventilation., D: LPG + ventilation. |
| Using solid fuels for cookingHouseholds continue using traditional solid fuels (e.g., coal or biomass) for cooking according to their usual practices. | Behavioural | A: Solid fuel + no ventilation (control)., C: Solid fuel + ventilation. |
| No ventilation during cookingHouseholds continue cooking without installing additional ventilation facilities during the intervention period. | Behavioural | A: Solid fuel + no ventilation (control)., B: LPG + no ventilation. |
Primary outcome
Change in the Number of Ultrafine particles (UFP)
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Unit: particles/cm³, Measuring instrument: TSI NanoScan (TSI, USA), MicroPEM (PennEngineering, USA), Gillian5000 (Sensidyne, USA), Measurement method: Monitoring device sensors.
Change in the Concentrations of PM2.5
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Unit: ug/m3, Measuring instrument: TSI NanoScan (TSI, USA), MicroPEM (PennEngineering, USA), Gillian5000 (Sensidyne, USA), Bbair (Yuanrui Environmental Protection Technology Co., Ltd, China) , Measurement method: Monitoring device sensors.
Change in the Heart Rate Variability (HRV) Measured by 12-lead ECG
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Heart rate variability measured using standard 12-lead electrocardiogram (ECG). Measuring instrument: HeaLink heart rate sensor (Henan Link Medical Technology Co., Ltd., China), The time-domain indicators include:SDNN: Standard deviation of all normal-to-normal (NN) intervals over 24 hours / SDANN: Standard deviation of the average NN intervals calculated over 5-minute segments throughout 24 hours / RMSSD: Root mean square of successive differences between adjacent NN intervals over 24 hours. The frequency-domain indicators include: TP: Total power / LF: Low-frequency power / HF: High-frequency power / LF/HF: Ratio of low-frequency to high-frequency power.
Change in the Forced Vital Capacity (FVC)
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Forced Vital Capacity measured using spirometer (HI105; Chestgraph, Japan). Units of Measure: Liters. Method of Measurement: Standardized spirometric testing protocol.
Change in the Forced Expiratory Volume in 1 Second (FEV1)
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Forced Expiratory Volume in 1 Second measured using spirometer (HI105; Chestgraph, Japan). Units of Measure: Liters. Method of Measurement: Standardized spirometric testing protocol.
29 secondary outcomes
Change in the Concentrations of Specific Chemical Components in Particulate Matter
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Concentrations of Ozone (O₃)
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Concentrations of Black Carbon (BC)
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Systolic and Diastolic Blood Pressure
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Fractional Exhaled Nitric Oxide (FeNO)
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Pulse Wave Velocity (PWV)
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Incidence of Obesity and Central Obesity
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Incidence of Diabetes
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Incidence of Dyslipidemia
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Incidence of Hypertension
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Incidence of Acute Exacerbation of Chronic Bronchitis
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Incidence of Acute Respiratory Infection
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Forced Expiratory Flow at 75% of FVC (FEF75)
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Forced Expiratory Flow at 50% of FVC (FEF50)
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Forced Expiratory Flow at 25% of FVC (FEF25)
Time frame: 1 year, with follow-ups at 6, 1 protocol.2, 24, and 36 months
Change in the Peak Expiratory Flow (PEF)
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Cardio-Ankle Vascular Index (CAVI)
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Peripheral Arterial Tone (PAT) Index
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Environmental Noise Level
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Concentrations of Internal Exposure to PAHs and VOCs
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Concentrations of Internal Exposure to Metal Elements
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Concentrations of Total Volatile Organic Compounds (TVOCs)
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Concentrations of Nitrogen Dioxide (NO₂)
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Concentrations of PM1 / PM10
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in Air Temperature
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in Relative Humidity
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in Wind Speed
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in Wind Direction
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Change in the Environmental Microbial Aerosols
Time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Mar 2026.
Related trials for Cardiopulmonary Function
Recruiting
Early Cardiopulmonary Rehabilitation Bundle Functional Capacity and Outcomes of Cardiac Surgeries Patients
Cardiac Surgeries
Not yet recruiting
Bedside Assessment of Right Ventricular Output Lying in Prone Or Supine
Right Ventricular Function, Prone Position
Recruiting
Exploring the Effects of Aerobic Exercise Combined With BFRT on Patients With COPD
Chronic Obstructive Pulmonary Disease
Not yet recruiting
Effects of Tart Cherry and Aronia Extract Supplementation on Selected Physiological Parameters in Endurance-Trained Men
Cardiovascular Physiology
Active, not recruitingPhase 2
Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord Injury
Spinal Cord Injuries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Kuai Yu principal investigator
Huazhong University of Science and Technology
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cooking ventilation facilities, Using liquefied gas for cooking and Using solid fuels for cooking in people with Cardiopulmonary Function and Environmental Exposures, run by Huazhong University of Science and Technology at 3 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kuai Yu (+86 15172473088, yukuai5200@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in the Number of Ultrafine particles (UFP) (time frame: 1 year, with follow-ups at 6, 12, 24, and 36 months). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2026.